BRAF and malignant colon neoplasm: For the treatment of potentially resectable colon cancer with RAS and BRAF wild-type status, LCRC with FOLFOXIRI ± cetuximab is recommended to patients, while FOLFOXIRI ± bevacizumab is recommended for RCC patients.